Company Overview
Company Type: Private Company
Website: nexelis.com
Number of Employees: 21
Year Founded: 1989
Total Amount Raised (CAD mm)†: -
Total Rounds of Funding**:-
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Nexelis provides preclinical and clinical immunology laboratory services. It offers immunology-centric CRO that provides preclinical models and clinical assay development in single and multiplex formats and sample analysis for low, mid, and large-scale clinical testing. The company's services include immunological services, protein services, immunochemistry, functional viral and bacterial assays, cellular immunology, bioanalytical services, and preclinical services. Additionally, the company develops vaccines and immunotherapies in animals and humans. The company was founded in 1989 and is based in Laval, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
 4.6
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
 21
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Bouche, Benoit 
President, CEO & Director
Kalusyan, Vahe 
Chief Financial Officer
McGrath, Timothy J.
Chief Operating Officer

Key Board Members
Name
Title
Bouche, Benoit 
President, CEO & Director
Hooper, Herbert H.
Director
Lev, Eric B.
Director
McCarthy, Laurence R.
Director


Primary Industry Classification
Pharmaceuticals


Primary Office Location
525 Cartier West Blvd | Laval, QC | H7V 3S8 | Canada
Phone: 450 239 1605   

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Q2 Solutions LLC
Jan-11-2022
Unknown
-
-

Prior Investors
Ampersand Management LLC


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Current and Pending Subsidiaries / Investments
Company Name
Business Description
Geography
Primary Industry
LTM Total Rev.($mm)
LFQ Total Assets ($mm)
LFQ Total Debt ($mm)
Vaccines Clinical Bioanalytical Laboratory Located in Marburg, Germany of GlaxoSmithKline plc (Pending)
Vaccines Clinical Bioanalytical Laboratory Located in Marburg, Germany of GlaxoSmithKline plc comprises vaccines clinical bioanalytical laboratory. The asset is located in Germany.

Europe
Life Sciences Tools and Services
-
-
-
AIT Bioscience, LLC
AIT Bioscience, LLC provides bioanalytical contract research organization (CRO) and immunoassay testing services for pharmaceutical and biotechnical companies. The company provides pharmacokinetics/toxicokinetics (PK/TK) bioanalysis, biomarker analysis and immunogenicity (ADA/NAb) assays support services, including discovery analyses, LC-MS screening for method development, ligand binding assays (LBA), method transfer capabilities, and sample analyses for preclinical and clinical studies. It also provides analytical methods, sample logistics, and sample analyses for investigational drugs applications. In addition, the company develops and validates assays for molecules, peptide drugs, and antibody-based therapeutics. The company was incorporated in 2008 and is based in Indianapolis, Indiana. As of July 22, 2020, AIT Bioscience, LLC operates as a subsidiary of Nexelis.

United States and Canada
Life Sciences Tools and Services
8.00
-
-
ImmunXperts SA
ImmunXperts SA develops bioassays involving the human immune system. The company’s services includes immunogenicity, immuno-oncology, and cell therapy. It also provides In silico services, In vitro services, MAPPS assay, and In vivo and clinical services. ImmunXperts SA was founded in 2014 and is headquartered in Gosselies, Belgium. As of March 19, 2020, ImmunXperts SA operates as a subsidiary of Nexelis.

Europe
Life Sciences Tools and Services
-
-
-


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Jan-11-2022
Jan-10-2022
Merger/Acquisition
Target
Nexelis
Q2 Solutions LLC
Ampersand Management LLC
-
Jan-20-2021
-
Merger/Acquisition
Buyer
Vaccines Clinical Bioanalytical Laboratory Located in Marburg, Germany of GlaxoSmithKline plc
Nexelis
GlaxoSmithKline plc (nka:GSK plc (LSE:GSK))
-
Jul-22-2020
Jul-22-2020
Merger/Acquisition
Buyer
AIT Bioscience, LLC
Nexelis
HALO Capital Group
-
Mar-04-2020
Mar-19-2020
Merger/Acquisition
Buyer
ImmunXperts SA
Nexelis
Sambrinvest S.A.
-
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
Oct-12-2022
Company Conference Presentations
Nexelis Presents at World Vaccine Congress Europe 2022, Oct-12-2022 03:00 PM
Jan-11-2022
M&A Transaction Closings
Q2 Solutions LLC acquired unknown stake in Nexelis from Ampersand Management LLC.
Mar-30-2021
Client Announcements
Nexelis and JOINN Laboratories Sign Letter of Intent Entering Partnership to Support International Sponsors in China in the Bioanalytical Field
Jan-20-2021
M&A Transaction Announcements
Nexelis signed an asset purchase agreement to acquire vaccines clinical bioanalytical laboratory located in Marburg, Germany from GlaxoSmithKline plc (LSE:GSK).
Jul-22-2020
M&A Transaction Closings
Nexelis acquired AIT Bioscience, LLC.

M&A Advisors
Goodwin Procter LLP, Morgan Stanley Canada Limited


Advisors
M&A Advisors
Goodwin Procter LLP, Morgan Stanley Canada Limited


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 22, 2023 12:38 AM
Nexelis
Nexelis
Reports
88
GlobalData

Jul 27, 2023 06:03 AM
Nexelis
Nexelis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
19
GlobalData

Jun 28, 2023 04:16 AM
Nexelis
Nexelis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
19
GlobalData

Jun 16, 2023 03:00 AM
Nexelis
Nexelis
Reports
87
GlobalData

Mar 17, 2023 05:51 AM
Nexelis
Nexelis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
19
GlobalData

Mar 14, 2023 12:29 AM
Nexelis
Nexelis
Reports
87
GlobalData

Dec 13, 2022 03:17 AM
Nexelis
Nexelis
Reports
87
GlobalData

Nov 16, 2022 05:47 AM
Nexelis
Nexelis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20
GlobalData

Sep 19, 2022 08:45 AM
Nexelis
Nexelis
Reports
87
GlobalData

Jul 27, 2022 06:50 AM
Nexelis
Nexelis - Pharmaceuticals & Healthcare - Deals and Alliances Profile
Reports
20


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.


Upcoming Events
Date/Time
Type
Oct-15-2023
Conferences
Oct-16-2023
Company Conference Presentations
* Future Events are subject to change.

Key Board Members Details
Name
Title
Phone
Fax
Email
Bouche, Benoit 
President, CEO & Director
450-239-1605 x 6393
-
benoit.bouche@nexelis.com
Hooper, Herbert H.
Director
450 239 1605
-
-
Lev, Eric B.
Director
450 239 1605
-
-
McCarthy, Laurence R.
Director
450 239 1605
-

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Bouche, Benoit 
President, CEO & Director
450-239-1605 x 6393
-
benoit.bouche@nexelis.com
Kalusyan, Vahe 
Chief Financial Officer
450 239 1605
-

McGrath, Timothy J.
Chief Operating Officer
450 239 1605
-

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
